Piramal Pharma Limited (PPLPHARMA) AI Stock Analysis

• Market Cap: ₹252.56B
• Dividend Yield: 0.07%
• Average Volume (3M): 266.97K
• Price to Earnings (P/E): 256.9
• Beta (1Y): 0.54
• Revenue Growth: 9.08%
• EPS Growth: 249.08%
• Country: IN
• Employees: 6,719
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 1,329,248,200
• 10 Day Avg. Volume: 161,125
• 30 Day Avg. Volume: 266,967
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹233.00
• Price Target Upside: 21.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: ₹216.00 ▲(12.38% Upside)

Piramal Pharma Limited's financial performance is marked by strong revenue growth and a solid balance sheet, but is offset by inconsistent profitability and cash flow challenges. The technical analysis indicates neutral market sentiment, while the high P/E ratio raises valuation concerns despite a reasonable dividend yield. Improving operational efficiencies and consistent cash flow generation are key to enhancing the company's financial health.

Piramal Pharma Limited Business Overview & Revenue Model

Company Description

Piramal Pharma Limited (PPLPHARMA) is a leading pharmaceutical company based in India, operating across multiple sectors including contract development and manufacturing, consumer healthcare, and critical care. The company is known for its extensive portfolio of differentiated pharmaceutical products and services, which cater to various therapeutic areas and patient needs globally.

How the Company Makes Money

Piramal Pharma Limited generates revenue through several key streams. The company's contract development and manufacturing organization (CDMO) services provide customized solutions for drug development and manufacturing to pharmaceutical and biotech clients worldwide. Additionally, PPLPHARMA's consumer healthcare division sells a range of over-the-counter (OTC) products, contributing to its revenue. The critical care division focuses on providing high-quality critical care drugs and devices to hospitals and healthcare providers, further enhancing its earnings. Strategic partnerships and collaborations with global pharmaceutical companies also play a significant role in driving the company's revenue growth.

Piramal Pharma Limited Financial Statement Overview

Summary

Piramal Pharma Limited shows strong growth in revenue and maintains a robust gross profit margin. However, inconsistent net profit margins and fluctuating free cash flow highlight potential volatility and issues in profitability and cash flow generation, requiring improvement in operational cash flow management.

Income Statement

Piramal Pharma Limited has shown a steady increase in revenue over the years, indicating a positive growth trajectory. The gross profit margin is robust, standing at approximately 64.7% in 2025. However, net profit margins have been inconsistent, with significant fluctuations, highlighting potential volatility in bottom-line profitability. EBIT margin improved significantly in 2025, suggesting better operational efficiency, but the EBITDA margin remains moderately low, indicating room for improvement in operational cash flow generation.

Balance Sheet

The company maintains a solid equity base, with a debt-to-equity ratio of 0.60 in 2025, reflecting a balanced capital structure and manageable leverage. Return on Equity (ROE) shows variability, indicating fluctuating profitability relative to shareholder investments. The equity ratio is healthy, suggesting a stable asset-financing structure primarily through equity, which reduces financial risk.

Cash Flow

Operating cash flow has been relatively stable, but free cash flow has seen significant fluctuations, indicating potential issues with capital expenditure management. The operating cash flow to net income ratio in 2025 is notably high, suggesting effective cash conversion from profits. However, the free cash flow growth rate has been inconsistent, raising concerns about sustainable cash generation capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	91.51B	91.51B	81.71B	70.82B	65.59B	58.87B
Gross Profit	44.04B	59.20B	49.09B	10.98B	37.91B	16.46B
EBITDA	15.06B	14.04B	13.67B	8.46B	12.60B	12.97B
Net Income	911.30M	911.30M	178.20M	-1.86B	3.76B	5.71B
Balance Sheet
Total Assets	156.78B	156.78B	153.12B	145.23B	127.97B	57.57B
Cash, Cash Equivalents and Short-Term Investments	5.21B	5.21B	5.02B	6.60B	3.79B	1.62B
Total Debt	48.56B	48.56B	47.10B	56.37B	41.28B	1.74B
Total Liabilities	75.52B	75.52B	74.00B	77.49B	61.00B	16.56B
Stockholders Equity	81.25B	81.25B	79.11B	67.73B	66.97B	41.01B
Cash Flow
Free Cash Flow	0.00	2.28B	2.92B	-4.81B	-1.23B	-233.90M
Operating Cash Flow	0.00	8.92B	10.05B	4.84B	7.66B	347.20M
Investing Cash Flow	0.00	-4.77B	-4.34B	-13.39B	-18.12B	-43.83B
Financing Cash Flow	0.00	-4.41B	-4.22B	8.18B	7.94B	44.94B

Piramal Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 192.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Negative. The current price of 192.2 is below the 20-day moving average (MA) of 199.10, below the 50-day MA of 201.06, and below the 200-day MA of 222.86, indicating a bearish trend. The MACD of -4.00 indicates Positive momentum. The RSI at 42.39 is Neutral, neither overbought nor oversold. The STOCH value of 34.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PPLPHARMA.

Piramal Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JBCHEPHARM	72 Outperform	₹266.37B	38.70		0.90%	11.56%	16.30%
GLAND	68 Neutral	₹317.42B	41.21		0.91%	-2.34%	6.64%
IPCALAB	66 Neutral	₹347.03B	44.57		0.29%	11.49%	35.00%
ASTRAZEN	66 Neutral	₹216.47B	187.03		0.39%	32.48%	-28.34%
PFIZER	61 Neutral	₹243.64B	30.13		0.67%	4.35%	32.89%
PPLPHARMA	60 Neutral	₹252.56B	256.86		0.07%	9.08%	249.08%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.26%	22.80%	-2.27%

Piramal Pharma Limited Corporate Events

Piramal Pharma Limited’s 5th AGM: Resolutions Passed and Shareholder Engagement Enhanced

Piramal Pharma Limited successfully conducted its 5th Annual General Meeting (AGM) on July 30, 2025, via video conference, ensuring compliance with regulatory guidelines. All proposed resolutions were passed with the requisite majority, demonstrating strong shareholder support and effective governance practices. The AGM proceedings were webcast for transparency, and e-voting facilities were provided to facilitate shareholder participation, reflecting the company’s commitment to leveraging technology for stakeholder engagement.

Piramal Pharma Receives ESG Rating from NSE Sustainability

Piramal Pharma Limited has been assigned an ESG Rating of ’61’ for the fiscal year 2023-24 by NSE Sustainability Ratings and Analytics Limited. This rating, which the company did not solicit, reflects the company’s performance in environmental, social, and governance aspects based on publicly available data. The rating could impact the company’s reputation and stakeholder perceptions regarding its commitment to sustainable practices.